ZHIGANG XIA^1,#, MENGYAO TIAN^1,#, YUCAI CHENG¹, WENFANG YI¹, ZEFAN DU^1,2, TIANWEN LI^1,2, YUCHEN WEN¹, LINDI LI^1,2, YONG LIU^1,2,*, CHUN CHEN^1,*

Oncology Research, Vol.32, No.6, pp. 1109-1118, 2024, DOI:10.32604/or.2024.049792 - 23 May 2024

Abstract Background: Chimeric antigen receptor T (CAR-T) cell therapy has achieved marked therapeutic success in ameliorating hematological malignancies. However, there is an extant void in the clinical guidelines concerning the most effective chemotherapy regimen prior to chimeric antigen receptor T (CAR-T) cell therapy, as well as the optimal timing for CAR-T cell infusion post-chemotherapy. Materials and Methods: We employed cell-derived tumor xenograft (CDX) murine models to delineate the optimal pre-conditioning chemotherapy regimen and timing for CAR-T cell treatment. Furthermore, transcriptome sequencing was implemented to identify the therapeutic targets and elucidate the underlying mechanisms governing the treatment regimen.… More >

Natalia Roque^1,#, Diana Matias^2,#, Joana Balça-Silva³, Valéria Pereira Ferrer⁴, Luciana Santos Pessoa¹, Tania Cristina Leite de Sampaio e Spohr^1,5,*

Oncologie, Vol.24, No.3, pp. 371-411, 2022, DOI:10.32604/oncologie.2022.024035 - 19 September 2022

Abstract Cancer is one of the deadliest diseases with a cure far from being found. Despite the extraordinary advances in the therapy approaches, only a few patients respond to treatments. The tumor microenvironment (TME) plays a crucial role in cancer progression by contributing to the chemoresistance. Thus, emerging efforts are being made in nanotechnology research focusing on nanoparticles’ potential role and their application in immune system modulation. Moreover, the omics have contributed to bioengineering and nanotechnology development by elucidating the mechanisms of cancer and specific biomarkers that could be used as new therapeutic targets. Furthermore, the More >

FRANCESCO MAININI^*

BIOCELL, Vol.45, No.5, pp. 1171-1173, 2021, DOI:10.32604/biocell.2021.017399 - 12 July 2021

Abstract Adoptive cell therapy and Immune Checkpoint Blockade Inhibitors have recently revolutionized the field of oncology. However, these types of immunotherapeutic approaches have limited success in treating solid tumors. In particular, chimeric antigen receptor (CAR)-T cells efficacy is hampered by immunosuppressive signals in the tumor microenvironment (TME) and by a limited infiltration of re-infused T cells to the tumor site. The field of nanobiotechnology applied to oncology is also rapidly expanding. Nanoparticles-based delivery systems can be employed to modulate the activity of immune cells present in the TME enhancing the efficacy of CAR-T cells. Interestingly, nano-backpacks More >